Imipenem+Relebactam
Phase 3Small molecule
Imipenem+Relebactam is one of 21 small molecule programs targeting Liver. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
25 competitors in Liver
#DrugCompanyPhaseTrials
1Sunlenca
GileadApproved
Afinitor
NovartisPhase 3
Fetroja
ShionogiPhase 3
Tygacil
PPrism Pharmaceuticals
Phase 3
Xerava
TTetraphase Pharmaceuticals, Inc
Phase 3
Azactam
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Pipracil
WWyeth-Lederle Vaccines
Phase 3
Aztreonam-Avibactam
PfizerPhase 3
CAZ-AVI
PfizerPhase 3
Imipenem+Relebactam
WWake Forest University Health Sciences
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver1 trial
Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase-producing Enterobacterales Undergoing Liver Transplantation: a Stepped Wedge Cluster Randomization Trial
Not yet recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 3·NCT07759453·168 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Imipenem+Relebactam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details